• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Adjuvant endocrine therapy of primary operable breast cancer. Report on the Copenhagen breast cancer trials.

作者信息

Palshof T, Mouridsen H T, Daehnfeldt J L

出版信息

Eur J Cancer (1965). 1980;Suppl 1:183-7.

PMID:7032931
Abstract
摘要

相似文献

1
Adjuvant endocrine therapy of primary operable breast cancer. Report on the Copenhagen breast cancer trials.原发性可手术乳腺癌的辅助内分泌治疗。哥本哈根乳腺癌试验报告。
Eur J Cancer (1965). 1980;Suppl 1:183-7.
2
Symposium on the management of early breast cancer (stages I and II). Part II: Clinical experience with treatment methods. 5. Adjuvant endocrine therapy.
Can J Surg. 1981 Jul;24(4):379-84.
3
Therapeutic effect of tamoxifen versus combined tamoxifen and diethylstilboestrol in advanced breast cancer in postmenopausal women.
Eur J Cancer (1965). 1980;Suppl 1:107-10.
4
[Internal endocrine therapy of breast cancer].
Gan To Kagaku Ryoho. 1984 May;11(5):989-98.
5
The tamoxifen trial - a double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer.
Eur J Cancer (1965). 1980;Suppl 1:83-8.
6
Adjuvant chemotherapy, anti-estrogen therapy and immunotherapy for stage II breast cancer.
Eur J Cancer (1965). 1980;Suppl 1:189-95.
7
The nature of tamoxifen action in the control of female breast cancer.他莫昔芬在女性乳腺癌控制中的作用本质。
In Vivo. 2001 Jul-Aug;15(4):319-25.
8
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.来曲唑与他莫昔芬作为绝经后内分泌反应性早期乳腺癌女性初始辅助治疗的五年比较：BIG 1-98研究更新
J Clin Oncol. 2007 Feb 10;25(5):486-92. doi: 10.1200/JCO.2006.08.8617. Epub 2007 Jan 2.
9
Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.利用雌激素受体信息在美国推广乳腺癌辅助多药化疗和他莫昔芬：1975 - 1999年
J Natl Cancer Inst Monogr. 2006(36):7-15. doi: 10.1093/jncimonographs/lgj003.
10
Preliminary report of a controlled trial in advanced breast cancer comparing tamoxifen with conventional hormone therapy.一项比较他莫昔芬与传统激素疗法治疗晚期乳腺癌的对照试验的初步报告。
Cancer Treat Rep. 1976 Oct;60(10):1461-2.

引用本文的文献

1
Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer.雌激素受体调节剂与下调剂：绝经后乳腺癌女性的最佳应用
Drugs. 2007;67(16):2335-53. doi: 10.2165/00003495-200767160-00004.
2
CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study).CMF方案与交替使用CMF/EV方案在可手术乳腺癌辅助治疗中的比较。一项单中心随机临床试验（那不勒斯GUN-3研究）。
Br J Cancer. 1995 Jun;71(6):1283-7. doi: 10.1038/bjc.1995.248.
3
Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control--preliminary results of a 4-arm randomised trial. The French Adjuvant Study Group.
绝经后可切除的淋巴结阳性乳腺癌患者。他莫昔芬与FEC 50（6个周期）、FEC 50（6个周期）加他莫昔芬与对照组——一项四臂随机试验的初步结果。法国辅助治疗研究组。
Drugs. 1993;45 Suppl 2:60-7. doi: 10.2165/00003495-199300452-00010.
4
Chemotherapy of breast cancer.乳腺癌的化疗
Med Oncol Tumor Pharmacother. 1984;1(3):169-92. doi: 10.1007/BF02934139.
5
Antiestrogen treatment of postmenopausal women with primary high risk breast cancer.对绝经后原发性高危乳腺癌女性进行抗雌激素治疗。
Breast Cancer Res Treat. 1983;3(1):77-84. doi: 10.1007/BF01806237.
6
Adjuvant trial for stage II receptor-positive breast cancer: CMF vs. CMF + tamoxifen in a single centre.
Breast Cancer Res Treat. 1988 May;11(2):179-86. doi: 10.1007/BF01805842.
7
Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.血清CA15-3联合癌胚抗原（CEA）和组织多肽抗原（TPA）检测在乳腺癌患者术后随访中的应用评估
Br J Cancer. 1991 Jul;64(1):154-8. doi: 10.1038/bjc.1991.260.